94. 原発性硬化性胆管炎 [臨床試験数:134,薬物数:105(DrugBank:37),標的遺伝子数:18,標的パスウェイ数:131

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03678480March 1, 202118/9/2018A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis;Cholangitis;Cholangitis, Sclerosing;Bile Duct Diseases;Biliary Tract Diseases;Digestive System Diseases;AdolescentDrug: HTD1801;Drug: Ursodeoxycholic AcidHighTide Biopharma Pty LtdNULLNot yet recruiting12 Years17 YearsAll104Phase 2NULL
2EUCTR2019-001015-23-FR13/05/202004/06/2020Study evaluating the efficacy of bezafibrate for people suffering of primary sclerosing cholangitisDouble blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy - BEZASCLER Adult patients with primary sclerosing cholangitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée
Product Name: bezafibrate
Product Code: C10AB02
INN or Proposed INN: BEZAFIBRATE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
104Phase 3France
3NCT04309773March 202018/10/2019Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid TherapyDouble Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid TherapyPrimary Sclerosing Cholangitis;CholestasisDrug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Drug: Placebo of Bezafibrate in addition to standard UDCA therapyAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 Years75 YearsAll104Phase 3France
4NCT03516006January 201720/9/2017Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing CholangitisIntra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing CholangitisPrimary Sclerosing CholangitisDrug: UCMSC;Drug: UDCAFuzhou General HospitalNULLActive, not recruiting18 Years65 YearsAll20Phase 1/Phase 2NULL
5EUCTR2015-003310-24-SE09/10/201501/09/2015Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy in Surveillance Patients with Primary Sclerosing Cholangitis (PSC)A Phase 3, Open-label, Randomized, Prospective Clinical Trial Evaluating the Efficacy of Stratified Treatment with Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy in Surveillance Patients with Primary Sclerosing Cholangitis (PSC) - UDCAPSCSURV Primary sclerosing cholangitis with or without concomitant inflammatory bowel disease included in an unlimited surveillance program for hepatobiliary and colorectal malignancy;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: Ursofalk
Product Name: Ursofalk
Sahlgrenska AcademyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 3Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01456468October 201114/10/2011Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing CholangitisCombination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot StudyCholangitis, SclerosingDrug: Oral all-trans retinoic acid (ATRA)Yale UniversityMayo ClinicCompleted18 Years80 YearsBoth19Phase 1United States
7NCT01088607October 201012/3/2010Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing CholangitisUrsodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstitution TrialPrimary Sclerosing CholangitisDrug: ursodeoxycholic acid (UDCA)University of TennesseeIcahn School of Medicine at Mount Sinai;Ann & Robert H Lurie Children's Hospital of Chicago;University of Colorado, Denver;University of California, San Francisco;University of Pittsburgh;Phoenix Children's Hospital;Children's Hospital of Philadelphia;Children's Healthcare of Atlanta;Children's Hospital Los Angeles;Texas Children's Hospital;Yale UniversityCompleted5 Years21 YearsAll27Phase 1United States;Canada
8NCT00059202April 200321/4/2003Trial of High-dose Urso in Primary Sclerosing CholangitisMulticentered Randomized Trial of High-dose Urso in Primary Sclerosing CholangitisSclerosing CholangitisDrug: Ursodeoxycholic AcidNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 Years75 YearsBoth150Phase 2/Phase 3United States